Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurochem. 2013 Aug;126 Suppl 1:118-24. doi: 10.1111/jnc.12318.

Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.

Author information

  • 1Department of Neurology, University of Marburg, Marburg, Germany. buerk@med.uni-marburg.de

Abstract

Friedreich ataxia (FRDA) is a progressive neurodegenerative disorder associated with ataxia, dysarthria, pyramidal tract signs, sensory loss, cardiomyopathy and diabetes. There is no cure for FRDA so far. Studies of the natural history of the disease and future therapeutic trials require development of appropriate outcome markers. Since any therapeutic benefit is expected to modulate deterioration over time rather than to reverse disability, potential outcome measures must be sensitive instruments carefully analysed for their significance. Clinical scales may represent an appropriate measuring tool. Over the last few years the construction, evaluation and validation of sensitive clinical scales for the assessment of disease severity and progression in ataxia have had considerable impact on our understanding of the disease. Currently, there are three different scales that are most frequently applied: The International Cooperative Ataxia Rating Scale (ICARS), the Friedreich Ataxia Rating Scale (FARS) and the Scale for the Assessment and Rating of Ataxia (SARA). All scales have been validated and compared with regard to their testing properties.

© 2013 International Society for Neurochemistry.

KEYWORDS:

FRDA; ataxia; scales

PMID:
23859347
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk